MRKMerck Sharp & Dohme LLCRunning, no new patients
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
Papillomavirus Infections
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 6,033 (final count)
- Started
- Feb 27, 2020
- Main results expected
- Jan 15, 2027
- Fully finished
- Aug 13, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of HPV 16/18/31/33/45/52/58-related 6-month Persistent Oral Infection
Measured over: Up to Month 90
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04199689 · record last updated 2026-10-20 · checked 2026-11-09 15:47 UTC